{
    "nctId": "NCT00002854",
    "briefTitle": "High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer",
    "officialTitle": "PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "Feasibility of two cycles of high dose chemotherapy with stem cell reinfusion",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed advanced carcinomas of the following types:\n\n  * Breast carcinoma that is ineligible for or patient has refused participation in a higher priority protocol in the following categories:\n\n    * Stage II disease with at least 10 involved lymph nodes and no evidence of disease (NED) following surgery\n    * Stage III disease rendered surgically NED with or without radiotherapy\n    * Stage IV disease following partial response (PR) or complete response (CR) to surgery, chemotherapy, or radiotherapy\n\n      * Prior high dose chemotherapy allowed at discretion of investigator\n      * No chemoresistant disease rendered surgically NED\n    * Locoregionally recurrent disease within 2 years of breast conservation with or without chemotherapy\n* Stage III/IV ovarian cancer\n\n  * PR/CR following debulking surgery and/or chemotherapy\n  * Ineligible for or refused participation in higher priority protocols\n* Primary soft tissue sarcoma with high-grade disease greater than 10 cm or that is metastatic\n\n  * Rendered surgically NED or achieved PR/CR on any chemotherapeutic or immunotherapeutic regimen\n  * Ineligible for or refused participation in higher priority protocols\n* Malignant melanoma in the following categories:\n\n  * Ulcerative primary tumor with any number of completely resected metastatic lymph nodes\n  * Stage II disease with more than 4 involved nodes rendered NED\n  * Stage III disease rendered surgically NED or achieved PR/CR on any chemotherapeutic or immunotherapeutic regimen\n* Osteosarcoma that is ineligible for or refused participation in higher priority protocols\n\n  * Resected primary with less than 50% tumor necrosis on pathologic review\n  * Metastatic disease rendered surgically NED or PR/CR on any chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen\n* The following diseases rendered surgically NED or that achieved PR/CR on any chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen also eligible:\n\n  * Small cell bone carcinoma\n  * Metastatic Ewing's sarcoma\n  * Metastatic gastrointestinal malignancy\n  * Recurrent Wilms' tumor\n* No CNS metastases\n* No current histologically confirmed bone marrow metastases\n\n  * Prior bone metastases with resolution at time of entry permitted\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* Physiologic 18 to 55\n\nPerformance status:\n\n* Karnofsky 80%-100%\n\nHematopoietic:\n\n* Absolute neutrophil count greater than 1,500/mm3\n* Platelet count greater than 120,000/mm3\n* Hemoglobin greater than 10 g/dL\n\nHepatic:\n\n* Bilirubin less than 1.5 mg/dL\n* AST/ALT less than 3 times normal\n\nRenal:\n\n* Creatinine less than 1.4 mg/dL\n* Creatinine clearance at least 70 mL/min\n* No history of hemorrhagic cystitis\n\nCardiovascular:\n\n* Ejection fraction at least 55% by MUGA\n* No significant cardiac disease\n\nPulmonary:\n\n* FEV1 greater than 2 L\n* pO2 (room air) greater than 70 mm Hg\n* pCO2 (room air) less than 42 mm Hg\n* DLCO greater than 60% of predicted\n\nOther:\n\n* No potentially disabling psychosocial history\n* No organic or functional CNS dysfunction or other medical problem that would present party at undue risk\n* HIV negative\n* Hepatitis B surface antigen negative\n* No hearing loss greater than 40 decibels\n* No contraindication to the following procedures:\n\n  * Collection by apheresis of up to 16 x 10 to the 8th mononuclear cells mobilized by G-CSF\n  * Collection of autologous bone marrow, if needed\n* No second malignancy except:\n\n  * Nonmelanomatous skin cancer\n  * Carcinoma in situ of the cervix\n* Not pregnant or nursing\n* Adequate contraception required of fertile patients\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* See Disease Characteristics\n* At least 4 weeks since prior immunotherapy\n\nChemotherapy:\n\n* See Disease Characteristics\n* No more than 3 prior chemotherapy regimens (excluding adjuvant therapy)\n* No more than 200 mg per square meter of prior cisplatin\n* No more than 800 mg per square meter of prior carboplatin\n* No prior exposure to greater than 1,000 mg per square meter of \"24-hour paclitaxel equivalents\" (using a 1:1.3 ratio between paclitaxel doses given by 24-hour infusion and by 3-hour infusion)\n* At least 4 weeks since prior chemotherapy\n\nEndocrine therapy:\n\n* Not specified\n\nRadiotherapy:\n\n* No prior radiotherapy to more than 20% of bone marrow\n* At least 4 weeks since prior radiotherapy\n\nSurgery:\n\n* See Disease Characteristics",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}